• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, December 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Janus bases among The Scientist’s Top Innovations of 2019

Bioengineer by Bioengineer
December 5, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Invented at Carnegie Mellon, the bivalent nucleic acid recognition platform is being used to develop treatments for rare genetic diseases

IMAGE

Credit: Carnegie Mellon University


The Scientist Magazine has named Janus bases as one of its Top 10 Innovations of 2019. Carnegie Mellon University Chemistry Professor Danith Ly invented the molecules, and they are being used to create new treatments for genetic diseases and disorders.

Janus bases are used to make two-sided synthetic analogs to DNA and RNA. The molecules can recognize and bind to DNA and RNA under normal physiological conditions, making them a promising platform for treating a wide range of genetic conditions including neurological diseases and muscular dystrophies.

Janus bases are being developed by NeuBase Therapeutics as a novel molecular platform for RNA-targeting drugs that silence or alter the expression of genes for the treatment of rare genetic diseases. NeuBase was founded and is led by CEO Dietrich Stephan, an alumnus of Carnegie Mellon’s Department of Biological Sciences. Ly serves as the company’s chief scientific officer.

Ly, who directs Carnegie Mellon’s Biomolecular Design and Discovery Institute, is a leading expert in creating peptide nucleic acids (PNAs). PNAs contain the same base pairs as DNA and RNA, but have a synthetic backbone. To further this technology, Ly created Janus bases, a set of bivalent nucleic acid recognition elements that can bind to any possible combination found in the genetic code. As a result, PNAs made with Janus bases can enter the double helix of DNA and RNA, search for detrimental sequences and bind to each side of the two strands and prevent a gene from malfunctioning.

Neubase uses PNAs with Janus bases to target and bind to mutant RNA and silence harmful genes by preventing translation or altering splicing of the genetic material. As a result, harmful proteins that cause disease are no longer produced.

###

Ly’s early work on Janus bases was made possible through a gift from the DSF Charitable Foundation to Carnegie Mellon’s Center for Nucleic Acids Science & Technology.

In its annual list of Top 10 Innovations, The Scientist identifies the latest and greatest tools, technologies and techniques in the life sciences. The innovations included on the list are selected by expert panels of independent judges. The Scientist is a publication for life-science professionals that is dedicated to covering a wide range of biological fields.

Media Contact
Jocelyn Duffy
[email protected]
412-268-9982

Original Source

https://www.cmu.edu/mcs/news-events/2019/1202_janus-bases-top-innovation.html

Tags: BiochemistryBiologyBiotechnologyChemistry/Physics/Materials SciencesGene TherapyGenesGeneticsMedicine/HealthneurobiologyPharmaceutical Sciences
Share13Tweet8Share2ShareShareShare2

Related Posts

BAF155 Drives Brain Myelination, Autism Behaviors in Mice

December 21, 2025

TMEM120A Regulates Fat Lipids via ER CoA Channel

December 21, 2025

Empowerment Model Boosts COPD Patients via Telenursing

December 21, 2025

Insights from Canadian Physicians on Deprescribing in Seniors

December 21, 2025
Please login to join discussion

POPULAR NEWS

  • Nurses’ Views on Online Learning: Effects on Performance

    Nurses’ Views on Online Learning: Effects on Performance

    70 shares
    Share 28 Tweet 18
  • NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    71 shares
    Share 28 Tweet 18
  • Unraveling Levofloxacin’s Impact on Brain Function

    53 shares
    Share 21 Tweet 13
  • Exploring Audiology Accessibility in Johannesburg, South Africa

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

BAF155 Drives Brain Myelination, Autism Behaviors in Mice

TMEM120A Regulates Fat Lipids via ER CoA Channel

Hidden Deforestation from Global Mining in 21st Century

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 70 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.